AG Mednet Joins Forces with Netherlands-based CRO Cardialysis for Efficient Cardiovascular Clinical Trials


Company News Release

Speed, efficiency, and accuracy are vital to the success of clinical trials.

Speed, efficiency and accuracy are vital to the success of clinical trials. With large amounts of data collected and significant room for data submission errors, there is even greater potential to disqualify participating patients or expose subjects to unnecessary risky procedures due to data errors.

To address these needs in clinical trials, Cardialysis, an independent Clinical Research Organization (CRO), has selected AG Mednet, the leading quality compliance company as preferred provider for image data submission and collection.

With more than 30 years of experience as a full-service CRO and Core Laboratory specializing in cardiology, Cardialysis has an established network of more than 1,200 sites world-wide and works with the top pharmaceutical, medical device and biotechnology organizations globally.

“We’re responsible for designing, managing, monitoring and reporting on all aspects of clinical-research trials,” said Teun Smits, Manager Business Development at Cardialysis. “As a CRO with Core Laboratory services working with AG Mednet, we’re experiencing significant efficiencies and convenience for participating clinical sites, and as such we expect even further improvement in the quality of the data collected and transferred compared to past trials. Electronic data submission and collection contributes to our goal of becoming a fully operated eCRO. ”

AG Mednet provides the market-leading functionality and support to collect clinical trial image data globally, properly de-identify it to ensure regulatory compliance, apply advanced, automated quality-assurance processes to ensure the data is protocol-compliant and readily usable, and deliver it reliably and securely to one or more trial repositories.

“With Cardialysis, we’re working on cardiology-related studies with two major medical device companies and more than 1,000 participating patients,” said Abraham Gutman, President & CEO of AG Mednet. “We are passionate about working with organizations that are leading the industry in a positive direction and we see Cardialysis as doing exactly that. We look forward to continued collaboration with Cardialysis on future clinical trials.”

For more information about AG Mednet’s work with clinical research organizations, imaging trial sponsors, imaging core labs and principal investigators, please visit

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.